Program: Sunday (23.10.2016)

07:30 – 08:30

Satellite Symposium (by Mundipharma EDO GmbH) The Evolution of Chemotherapy: Using the A-DAC Principle to Unlock New Treatment Options in Hodgkin Lymphoma

  • Volker Diehl
  • 07:30–07:35

    The evolution of chemotherapy – an introduction from the chair

    • Volker Diehl
  • 07:35–07:45

    The A-DAC principle – introducing EDO-S101

    • Volker Diehl
  • 07:45–08:05

    Breaking through resistance – the potential for EDO-S101 (an overview of pre-clinical data in Hodgkin Lymphoma)

    • Antonello Pinto
  • 08:05–08:25

    EDO-S101: pre-clinical data in Multiple Myeloma and initial ndings from phase I in haematological malignancies

    • Christoph Driessen
  • 08:25–08:30

    Unlocking the potential – Q&A session

    • Volker Diehl

08:30 – 10:00

Scientific Session Interactive Case Discussions

  • Peter Borchmann
  • Richard Hoppe
  • John Raemaekers
  • 08:30–08:50

    Case Discussion #1: Early Unfavorable - PET driven?

    • Marc André
  • 08:50–09:10

    Case Discussion #2: HL during pregnancy

    • Ranjana Advani
  • 09:10–09:30

    Case Discussion #3: Late Relapse of HL

    • Paul J. Bröckelmann
  • 09:30–09:50

    Case Discussion #4: Relapsed/Refractory HL and PD-1i

    • Mark Hertzberg

10:30 – 12:00

Scientific Session MRD and Prediction

  • Michel Meignan
  • Pier Luigi Zinzani
  • 10:30–10:50

    Clinical – IPS and other scores

    • Jonathan Friedberg
  • 10:50–11:10

    Serum marker

    • Arjan Diepstra
  • 11:10–11:30

    Circulating cell-free DNA in HL

    • Peter Vandenberghe
  • 11:30–11:40

    Plasma vesicle-associated miRNAs as therapy response biomarkers in Hodgkin Lymphoma

    • Michiel Pegtel
  • 11:40–11:50

    Mid-treatment TARC and mid-treatment FDG-PET predict for progression free survival in classical Hodgkin Lymphoma

    • Wouter Plattel
  • 11:50–12:00

    A comprehensive analysis of Hodgkin Lymphoma seasonality across various geographic regions

    • Sven Borchmann

12:15 – 13:45

Satellite Symposium (by Amgen GmbH) New Insights in the Treatment and Management of Lymphoid Malignancies

  • Christoph Scheid
  • 12:15–12:20

    Welcome

    • Christoph Scheid
  • 12:20–12:35

    Impact of febrile neutropenia in the HD18 trial: nal analysis of the project “daily G-CSF versus Peg lgrastim”

    • Peter Borchmann
  • 12:35–13:05

    BiTE®: a new strategy for hematologic malignancies

    • Nicola Gökbuget
  • 13:05–13:35

    Multiple Myeloma: new treatment options for patients with Car lzomib

    • Christoph Scheid
  • Conclusion and closing remarks

    • Christoph Scheid

14:00 – 15:30

Workshop Immunomodulation

  • Philippe Armand
  • Tim Illidge
  • Biological basis for PD-1 based immunotherapy

    • Marit Roemer
  • How do we rationally combine immune checkpoint therapy for optimal impact

    • Stephen Ansell
  • Radiotherapy and immunotherapy combinations

    • Tim Illidge
  • Allo transplant vs checkpoint blockade in HL

    • Philippe Armand

14:00 – 15:30

Workshop Current Concepts in Allo TX

  • Anton Hagenbeek
  • Anna Sureda
  • Allo-SCT in RR HL. The state of the art

    • Norbert Schmitz
  • The impact of the stem cell source (HLA id Sib vs MUD vs CB vs Haplo) in the outcome after allo-SCT

    • Luca Castagna
  • The role of allogeneic stem cell transplantation in the era of new drugs

    • Anna Sureda

14:00 – 15:30

Workshop Grey Zone Lymphoma

  • Jonathan Friedberg
  • Wyndham Wilson
  • Pathology of grey zone lymphomas

    • Stefania Pittaluga
  • Joint pediatric Hodgkin and Non-Hodgkin lymphoma study group on grey zone lymphoma in children and adolescents

    • Christine Mauz-Körholz
  • Retrospective study of grey zone lymphomas

    • Andrew Evens
  • Mediastinal grey zone lymphomas: are they more like PMBL or nsHL?

    • Wyndham Wilson

16:00 – 17:30

Satellite Symposium (by primeOncology) Relapsed / Refractory Hodgkin Lymphoma: Nuances in Therapeutic Strategies to Improve Outcomes – a Case-Based Program

  • Andreas Engert
  • 16:00–16:00

    Welcome and introduction

    • Andreas Engert
  • 16:00–16:10

    Avoiding relapse of Hodgkin Lymphoma (HL): have we moved the needle?

    • Andreas Engert
  • 16:10–16:15

    Case #1: patient with advanced HL who relapses 18 months after initial therapy

    • Pier Luigi Zinzani
  • 16:15–16:30

    Relapsed / refractory HL: therapeutic options prior to autologous stem cell transplant (ASCT)

    • Pier Luigi Zinzani
  • 16:30–16:35

    Case #2: patient with bulky relapsed HL occurring 10 months following initial therapy

    • Craig H. Moskowitz
  • 16:35–16:50

    Post-ASCT relapse: making the most of what we have

    • Craig H. Moskowitz
  • 16:50–16:55

    Q&A

  • 16:55–17:00

    Case #3: patient with HL who has relapsed following ASCT

    • Tim Illidge
  • 17:00–17:15

    Novel agents in HL: what, how, and when should they be integrated?

    • Tim Illidge
  • 17:15–17:25

    Challenge the experts

  • 17:25–17:30

    prIME PointsTM

    • Andreas Engert

17:45 – 19:45

Main Program Opening Ceremony

  • Movie: A History of Hodgkin Lymphoma

  • Key Note Lectue

  • Awards Ceremony

20:00

Main Program Get Together

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.